This transcript has been edited for clarity.

Good morning. My name is Barbara Wirostko, MD, FARVO, and I am an adjunct professor at the University of Utah, a glaucoma specialist, and also the co-founder and chief medical officer for Qlaris Bio. It’s been an honor to present at the American Glaucoma Society meeting this past Saturday, where I spoke about what we are doing at Qlaris.

We are currently in clinical development with a novel IOP-lowering agent that is actually a vasodilatory compound. It works to vasodilate the outflow system distal to the trabecular meshwork, and it also has the potential to improve perfusion to the optic nerve head.

At the American Glaucoma Society meeting, I covered some of the top-line data. We now have determined the optimum concentration and a once-a-day PM dosing regimen. We have an excellent safety profile because our formulation is preservative-free, isotonic, and pH neutral.

We’ve also explored the unmet need for additional IOP lowering. In the Apterix study, we added QLS-111 on top of a current latanoprost regimen and were able to show roughly 3.2 to 3.6 mmHg of additional IOP reduction.

There is truly an unmet need here. Often, when we treat patients, we start with an IOP-lowering agent. Although laser and other surgical procedures exist, patients remain on topical therapy, and more options are needed.

QLS-111 provides a novel mechanism with an ideal safety profile. A once-a-day therapy combining latanoprost and QLS-111 in a fixed-dose combination holds a lot of promise for our patients. Thank you. GP